Compare ICMB & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICMB | SCLX |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.8M | 139.3M |
| IPO Year | N/A | N/A |
| Metric | ICMB | SCLX |
|---|---|---|
| Price | $2.82 | $16.55 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 40.8K | ★ 120.8K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | ★ 18.70% | N/A |
| EPS Growth | ★ 31.51 | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | $17,931,778.00 | ★ $40,360,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.75 | $749.70 |
| P/E Ratio | $7.25 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.46 | $3.60 |
| 52 Week High | $3.47 | $34.27 |
| Indicator | ICMB | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 47.40 | 41.66 |
| Support Level | $2.74 | $18.34 |
| Resistance Level | $2.90 | $20.62 |
| Average True Range (ATR) | 0.09 | 1.46 |
| MACD | -0.01 | -0.39 |
| Stochastic Oscillator | 21.87 | 3.10 |
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). Its investment objective is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.